A reply to “Cardiac dysfunction due to Osimertinib”

We appreciate the interest in our article detailing the clinical characteristics of osimertinib-induced left ventricular ejection fraction (LVEF) reduction [1] and Anand ’s comments. We also referred to some limitations in the discussion, but as he pointed out, our study was retrospective and only 65% of patients were able to undergo echocardiogram before and after osimertinib. The number of analysis object cases is not sufficient at all. Such cases as requiring e chocardiogram after osimertinib administration are likely to be cases of suspected osimertinib-induced cardiac dysfunction and we may overestimate the decrease in LVEF associated with osimertinib.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research